Leading CRO in Hypothalamo Pituitary Disorder (HPD) trials
Accelsiors prides itself with being among the leader CROs in Hypothalamo Pituitary Disorders (HPD). We have been or are involved in over 80% of all long acting rhGH development programs. Our nearly 2 decads of experience in this special research area and with this significantly contributed to marketing authorization of several products aimed to treat HPDs, but also to very successful out-licensing of ongoing development programs.
Take advantage from our broad experience and professional background in HPD’s clinical trials.
Over the course of years, Accelsiors has conducted:
- over 30 Growth Hormone Deficiency (GHD), Acromegaly, Cushing’s, Adrenal Glands studies, GnRH agonists and antagonists
- from first in human Phase I to Phase III registration trials,
- collected, evaluated, analyzed and reported data of several thousand patients both in pediatric and adult population.
- Our team has excellent understanding of study endpoints and deep experience in assay validation also.
Do you need more professional help?
Feel free to ask Accelsiors’ Hypothalamo Pituitary Disorders (HPDs) clinical study experts! Contact us:
Write Us
Call Us: +36 1 299 0091
Request for Proposal
and we will schedule a meeting around your calendar!
Quick patient access…
Benefit from our established and trusted relationship with key recruiting sites globally – this extends to key opinion leaders on a global scale. We understand the status of competitive recruitment, the main success drivers and biggest drawbacks for patient recruitment. We will help you in selecting of high recruiting sites with proven quality records in all HPD indications, irrespective of whether pediatric or adult study.
…with decreased screening failure rates
Considering the extreme screening failure rates in these indications, Accelsiors medical monitors have assessed and interpreted thousands of laboratory and clinical results in different Hypothalamo Pituitary Disorders. Our experienced team will guide you how to decrease the screening failure rates, we ensure the best screening and effective ways of patient recruitment in this often challenging therapeutic area.
